Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 12 Sept 2026Clinical review pending
Saved on this device
!
New vascular event
Acute chest pain, focal neurological deficit or sudden limb ischaemia requires the relevant emergency pathway rather than a routine prevention review.
Action: Assess immediately, activate the appropriate acute cardiac, stroke or vascular service, and reconcile antithrombotic therapy without delaying reperfusion decisions.
Synopsis
Reduce myocardial infarction, stroke, limb events and mortality by treating peripheral arterial disease as established systemic atherosclerotic cardiovascular disease.
PAD is established cardiovascular disease even when leg symptoms seem mild.
New chest pain, focal neurological deficit or sudden painful cold limb is an emergency and must not wait for routine risk-factor review.
Limb progression
New rest pain, ulceration or gangrene warrants urgent vascular assessment even while cardiovascular preventive treatment continues.
Investigation priorities
01
Baseline lipid profile and liver transaminasesFirst step
Quantify atherogenic cholesterol and establish safety information before intensive lipid lowering.
Management branches
Initial prevention planBuild one coordinated vascular-risk prescription
PAD is diagnosed or a patient with established PAD enters ongoing care.
Confirm smoking, blood pressure, lipids, diabetes, renal function, diet, physical activity, bleeding history and all cardiovascular diagnoses and procedures.
Offer intensive statin treatment and select antiplatelet therapy according to NICE indications, contraindications, current anticoagulation and recent coronary or cerebrovascular treatment.
Key medicines
AtorvastatinOffer 80 mg orally once daily for secondary prevention; use a lower dose when interactions, adverse-effect risk or patient preference require it.Check baseline lipids and liver transaminases, pregnancy status where relevant, interacting medicines and unexplained muscle symptoms. Review two to three months after starting or changing treatment. The NICE page records that this recommendation involved off-label use in December 2023, so confirm current product authorisation when prescribing.
Clopidogrel (Milpharm 75 mg tablets)75 mg orally once daily when selected for long-term prevention of occlusive vascular events in PAD.Do not use in active pathological bleeding or severe hepatic impairment. Review anaemia, bleeding history, other antithrombotics and procedure plans. Concomitant omeprazole or esomeprazole is discouraged because reduced CYP2C19 activation can weaken the antiplatelet effect.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 12 Sept 2026; clinical approval remains outstanding.